Neurogen Corporation engages in the drug discovery and development with a focus on small molecule drugs for various disorders, including neurological diseases, pain, metabolic diseases, and inflammation. The company, through its Accelerated Intelligent Drug Discovery system, focuses on the development of drugs primarily relating to insomnia, pain, depression/anxiety, and obesity/diabetics. Its primary product candidate, insomnia compound, NG2-73, a phase II clinical trial product, is being developed to treat sleep disorders. The company is also developing vanilloid receptor-1, NGD-8243, a phase I clinical trial product, for the treatment of pain in collaboration with Merck Sharp &...